A detailed history of Blackstone Inc transactions in Autolus Therapeutics PLC stock. As of the latest transaction made, Blackstone Inc holds 20,485,611 shares of AUTL stock, worth $46.9 Million. This represents 0.35% of its overall portfolio holdings.

Number of Shares
20,485,611
Previous 20,485,611 -0.0%
Holding current value
$46.9 Million
Previous $71.3 Million 4.31%
% of portfolio
0.35%
Previous 0.31%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023

BUY
$1.74 - $3.27 $4.35 Million - $8.18 Million
2,500,000 Added 13.9%
20,485,611 $38.9 Million
Q4 2021

Feb 14, 2022

BUY
$5.1 - $7.0 $91.7 Million - $126 Million
17,985,611 New
17,985,611 $93.3 Million

Others Institutions Holding AUTL

About Autolus Therapeutics plc


  • Ticker AUTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 90,909,800
  • Market Cap $208M
  • Description
  • Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...
More about AUTL
Track This Portfolio

Track Blackstone Inc Portfolio

Follow Blackstone Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Blackstone Inc, based on Form 13F filings with the SEC.

News

Stay updated on Blackstone Inc with notifications on news.